Lynne Regan, PhD
Development of a Novel Class of Therapeutics for Bronchioalveolar Carcinoma
EGFR and HER-2 are two culprits that often cause the uncontrolled growth of lung cancer cells. Dr. Lynne Regan proposed to develop novel methods to prevent these proteins from being made in the cell, through targeting Hsp90, an important protein involved in protein folding and processing.
Dr. Regan has uncovered a novel class of Hsp90 inhibitors that can effectively kill lung cancer cells, and found drug combinations that become much more effective anti-tumor agents. Studies are ongoing to further investigate the scope and details of how these inhibitors induce cell death.